. Author manuscript; available in PMC: 2012 Dec 15.

Published in final edited form as: Clin Cancer Res. 2011 Oct 28;17(24):7634–7644. doi: 10.1158/1078-0432.CCR-11-1677

Table 1.

Changes in pharmacokinetic and pharmacokinetic parameters during the sunitinib treatment and withdrawal periods. The Wilcoxon signed rank test was used for comparing the change between time points during each period. Percent change was used for SUV_mean and SUV_max, whereas absolute changes were used for all other values. Css, concentration at steady state; met, metabolite.

	4/2 Schedule (n=8)				2/1 Schedule (n=8)
	Treatment		Withdrawal		Treatment		Withdrawal
	Median Change (Range)	p-value	Median Change (Range)	p-value	Median Change (Range)	p-value	Median Change (Range)	p-value
Sunitinib, Css (ng/mL)	63 (37 – 184)	0.005	−59 (−181 – −32)	0.008	62 (−32 – 162)	0.008	−51 (−104 – −23)	0.008
Sunitinib met, Css (ng/mL)	20 (14 – 39)	<0.001	−18 (−29 – −5)	0.008	21 (5 – 52)	0.008	−16 (−26 – −1)	0.008
VEGF (pg/mL)	168 (51 – 461)	0.008	−184 (−448 – −22)	0.008	100 (18 – 361)	0.008	−96 (−253 – −26)	0.008
SUV_mean (% change)	−16 (−100 – 0)	0.031	15 (−14 – 277)	0.047	−18 (−64 – 6)	0.109	19 (−5 – 200)	0.047
SUV_max (% change)	−34 (−100 – 4)	0.016	33 (−18 – 221)	0.078	−21 (−64 – 6)	0.039	28 (−33 – 251)	0.109